ARCHIVES

NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.

This article is from The Cancer Letter archive.

Vol. 30 No. 16 | April 16, 2004

Download PDF Visit The Full Archive

Related Articles

Genentech’s Ferrara Wins Lasker Award For VEGF Discovery

October 8, 2010

The Future of Cancer Centers: Demographics Informatics, Genetics, Will BE Major Influences, Robert Young Says

May 7, 1999

Gene Therapy Experiments Get RDAC Okay

August 10, 1990

FDA Caps Advisors’ Holdings To $50,000 In Firms Affected By Committee Meetings.

August 8, 2008

Creating the Modern Cancer Center

November 2, 2021

“With resources now constrained, the ability of NCI to be responsive to its constituencies has been compromised.”

July 7, 1995